 Abeona Therapeutics Inc NASDAQ: ABEO has announced updated data from Phase 12a trial for up to six years following treatment with EB-101 for recessive dystrophic epidermolysis bullosa RDEB. The data showed that investigator assessment of wound healing of over 50 from baseline was present in 69 of treated wounds n1826 at three years, 93 n1415 at four years, 80 n1215 at five years, and 80 n45 at six years. 